[1]
Sharma S. Tumor markers in clinical practice: General principles and guidelines. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. 2009 Jan:30(1):1-8. doi: 10.4103/0971-5851.56328. Epub
[PubMed PMID: 20668599]
[2]
Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers: A diagnostic tool. National journal of maxillofacial surgery. 2016 Jan-Jun:7(1):17-20. doi: 10.4103/0975-5950.196135. Epub
[PubMed PMID: 28163473]
[3]
Malati T. Tumour markers: An overview. Indian journal of clinical biochemistry : IJCB. 2007 Sep:22(2):17-31. doi: 10.1007/BF02913308. Epub
[PubMed PMID: 23105677]
Level 3 (low-level) evidence
[4]
Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS. Cancer biomarkers - current perspectives. The Indian journal of medical research. 2010 Aug:132():129-49
[PubMed PMID: 20716813]
Level 3 (low-level) evidence
[5]
Zygulska AL, Pierzchalski P. Novel Diagnostic Biomarkers in Colorectal Cancer. International journal of molecular sciences. 2022 Jan 13:23(2):. doi: 10.3390/ijms23020852. Epub 2022 Jan 13
[PubMed PMID: 35055034]
[6]
Upadhyay A. Cancer: An unknown territory; rethinking before going ahead. Genes & diseases. 2021 Sep:8(5):655-661. doi: 10.1016/j.gendis.2020.09.002. Epub 2020 Sep 18
[PubMed PMID: 34291136]
[7]
Hamilton JG, Waters EA. How are multifactorial beliefs about the role of genetics and behavior in cancer causation associated with cancer risk cognitions and emotions in the US population? Psycho-oncology. 2018 Feb:27(2):640-647. doi: 10.1002/pon.4563. Epub 2017 Oct 26
[PubMed PMID: 29024169]
[8]
Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of Gene-Environment Interactions on Cancer Development. International journal of environmental research and public health. 2020 Nov 3:17(21):. doi: 10.3390/ijerph17218089. Epub 2020 Nov 3
[PubMed PMID: 33153024]
[9]
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021 May:71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4
[PubMed PMID: 33538338]
[10]
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. American journal of preventive medicine. 2014 Mar:46(3 Suppl 1):S7-15. doi: 10.1016/j.amepre.2013.10.029. Epub
[PubMed PMID: 24512933]
[11]
Sewpersad S, Pillay TS. Historical perspectives in clinical pathology: Bence Jones protein-early urine chemistry and the impact on modern day diagnostics. Journal of clinical pathology. 2021 Apr:74(4):212-215. doi: 10.1136/jclinpath-2020-206675. Epub 2020 May 29
[PubMed PMID: 32471887]
Level 3 (low-level) evidence
[12]
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical chemistry. 2008 Dec:54(12):e11-79. doi: 10.1373/clinchem.2008.105601. Epub
[PubMed PMID: 19042984]
Level 1 (high-level) evidence
[13]
Duffy MJ. Clinical uses of tumor markers: a critical review. Critical reviews in clinical laboratory sciences. 2001 Jun:38(3):225-62
[PubMed PMID: 11451209]
[14]
Quintanilla-Martinez L, Tinguely M, Bonzheim I, Fend F. [Bone marrow biopsy: processing and use of molecular techniques]. Der Pathologe. 2012 Nov:33(6):481-9. doi: 10.1007/s00292-012-1647-z. Epub
[PubMed PMID: 23085692]
[15]
Vartanian K, Slottke R, Johnstone T, Casale A, Planck SR, Choi D, Smith JR, Rosenbaum JT, Harrington CA. Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. BMC genomics. 2009 Jan 5:10():2. doi: 10.1186/1471-2164-10-2. Epub 2009 Jan 5
[PubMed PMID: 19123946]
[16]
Magaki S, Hojat SA, Wei B, So A, Yong WH. An Introduction to the Performance of Immunohistochemistry. Methods in molecular biology (Clifton, N.J.). 2019:1897():289-298. doi: 10.1007/978-1-4939-8935-5_25. Epub
[PubMed PMID: 30539453]
[17]
Kim S, Park BK, Seo JH, Choi J, Choi JW, Lee CK, Chung JB, Park Y, Kim DW. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases. Scientific reports. 2020 Jun 1:10(1):8820. doi: 10.1038/s41598-020-65720-8. Epub 2020 Jun 1
[PubMed PMID: 32483216]
[18]
van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF, Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer. Guidelines for processing and reporting of prostatic needle biopsies. Journal of clinical pathology. 2003 May:56(5):336-40
[PubMed PMID: 12719451]
Level 1 (high-level) evidence
[19]
Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Söletormos G, van der Merwe E, Diamandis EP, National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clinical chemistry. 2008 Aug:54(8):e1-e10. doi: 10.1373/clinchem.2007.094144. Epub 2008 Jul 7
[PubMed PMID: 18606634]
Level 1 (high-level) evidence
[20]
Mosley AK, Brouwer KL. Heat treatment of human serum to inactivate HIV does not alter protein binding of selected drugs. Therapeutic drug monitoring. 1997 Aug:19(4):477-9
[PubMed PMID: 9263392]
[21]
Yin Y, Cao Y, Xu Y, Li G. Colorimetric immunoassay for detection of tumor markers. International journal of molecular sciences. 2010:11(12):5077-94. doi: 10.3390/ijms11125077. Epub 2010 Dec 7
[PubMed PMID: 21614193]
[22]
Hjemdahl P. Catecholamine measurements by high-performance liquid chromatography. The American journal of physiology. 1984 Jul:247(1 Pt 1):E13-20
[PubMed PMID: 6377918]
[23]
Zaha DC. Significance of immunohistochemistry in breast cancer. World journal of clinical oncology. 2014 Aug 10:5(3):382-92. doi: 10.5306/wjco.v5.i3.382. Epub
[PubMed PMID: 25114853]
[25]
Signoroni S, Vitellaro M, Sala P, Bertario L. Biomarkers in familial adenomatous polyposis: role and significance. Frontiers in bioscience (Scholar edition). 2010 Jan 1:2(2):413-21
[PubMed PMID: 20036957]
[26]
Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer. 1998 Apr 15:82(8):1419-42
[PubMed PMID: 9554517]
[27]
Virtanen C, Woodgett J. Clinical uses of microarrays in cancer research. Methods in molecular medicine. 2008:141():87-113
[PubMed PMID: 18453086]
[28]
Agrawal L, Engel KB, Greytak SR, Moore HM. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Seminars in cancer biology. 2018 Oct:52(Pt 2):26-38. doi: 10.1016/j.semcancer.2017.12.008. Epub 2017 Dec 16
[PubMed PMID: 29258857]
Level 3 (low-level) evidence
[29]
Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2006 Dec:78(4):125-9
[PubMed PMID: 17269614]
[30]
Coşkun A, Aarsand AK, Sandberg S, Guerra E, Locatelli M, Díaz-Garzón J, Fernandez-Calle P, Ceriotti F, Jonker N, Bartlett WA, Carobene A, European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation. Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study. Clinical chemistry and laboratory medicine. 2022 Mar 28:60(4):543-552. doi: 10.1515/cclm-2021-0283. Epub 2021 May 10
[PubMed PMID: 33964202]
[31]
Sturgeon C. Standardization of tumor markers - priorities identified through external quality assessment. Scandinavian journal of clinical and laboratory investigation. Supplementum. 2016:245():S94-9. doi: 10.1080/00365513.2016.1210334. Epub
[PubMed PMID: 27542005]
Level 2 (mid-level) evidence
[32]
Jassam N, Jones CM, Briscoe T, Horner JH. The hook effect: a need for constant vigilance. Annals of clinical biochemistry. 2006 Jul:43(Pt 4):314-7
[PubMed PMID: 16824284]
[33]
Reinsberg J. Interference by human antibodies with tumor marker assays. Hybridoma. 1995 Apr:14(2):205-8
[PubMed PMID: 7590781]
[34]
Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Best practice & research. Clinical endocrinology & metabolism. 2013 Oct:27(5):647-61. doi: 10.1016/j.beem.2013.05.011. Epub 2013 Jun 20
[PubMed PMID: 24094636]
[35]
Banfi G, Salvagno GL, Lippi G. The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. Clinical chemistry and laboratory medicine. 2007:45(5):565-76
[PubMed PMID: 17484616]
[36]
Horn PS, Pesce AJ. Reference intervals: an update. Clinica chimica acta; international journal of clinical chemistry. 2003 Aug:334(1-2):5-23
[PubMed PMID: 12867273]
[37]
Hayes DF. Biomarker validation and testing. Molecular oncology. 2015 May:9(5):960-6. doi: 10.1016/j.molonc.2014.10.004. Epub 2014 Oct 18
[PubMed PMID: 25458054]
Level 1 (high-level) evidence
[38]
Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2013:22(1):4-11. doi: 10.1159/000338393. Epub 2012 May 15
[PubMed PMID: 22584792]
[39]
Marques-Garcia F, Boned B, González-Lao E, Braga F, Carobene A, Coskun A, Díaz-Garzón J, Fernández-Calle P, Perich MC, Simon M, Jonker N, Aslan B, Bartlett WA, Sandberg S, Aarsand AK, European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation and Task Group for the Biological Variation Database. Critical review and meta-analysis of biological variation estimates for tumor markers. Clinical chemistry and laboratory medicine. 2022 Mar 28:60(4):494-504. doi: 10.1515/cclm-2021-0725. Epub 2022 Feb 10
[PubMed PMID: 35143717]
Level 1 (high-level) evidence
[40]
Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O, Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. The Journal of urology. 2008 Jun:179(6):2181-5; discussion 2185-6. doi: 10.1016/j.juro.2008.01.099. Epub 2008 Apr 18
[PubMed PMID: 18423743]
[41]
Coppolino G, Bolignano D, Rivoli L, Mazza G, Presta P, Fuiano G. Tumour markers and kidney function: a systematic review. BioMed research international. 2014:2014():647541. doi: 10.1155/2014/647541. Epub 2014 Feb 6
[PubMed PMID: 24689048]
Level 1 (high-level) evidence
[42]
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Annals of clinical biochemistry. 1998 Jan:35 ( Pt 1)():99-103
[PubMed PMID: 9463746]
[43]
Al-Taee IK, Al-Safar JJ, Al-Falahi YS, Al-Shamma IA. The Clinical Significance of beta2-microglobulin in End-Stage Renal Disease. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2003 Oct-Dec:14(4):492-6
[PubMed PMID: 17657122]
[44]
Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clinics in liver disease. 2015 May:19(2):309-23. doi: 10.1016/j.cld.2015.01.005. Epub 2015 Feb 27
[PubMed PMID: 25921665]
[45]
Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Seminars in cancer biology. 1999 Apr:9(2):67-81
[PubMed PMID: 10202129]
[46]
Narayanan S. Alkaline phosphatase as tumor marker. Annals of clinical and laboratory science. 1983 Mar-Apr:13(2):133-6
[PubMed PMID: 6859804]
[47]
Kim SH, Shin KH, Moon SH, Jang J, Kim HS, Suh JS, Yang WI. Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. Cancer medicine. 2017 Jun:6(6):1311-1322. doi: 10.1002/cam4.1022. Epub 2017 May 11
[PubMed PMID: 28493412]
[48]
Jurisic V, Radenkovic S, Konjevic G. The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. Advances in experimental medicine and biology. 2015:867():115-24. doi: 10.1007/978-94-017-7215-0_8. Epub
[PubMed PMID: 26530363]
Level 3 (low-level) evidence
[49]
Kong HY, Byun J. Emerging roles of human prostatic Acid phosphatase. Biomolecules & therapeutics. 2013 Jan:21(1):10-20. doi: 10.4062/biomolther.2012.095. Epub
[PubMed PMID: 24009853]
[50]
Beketic-Oreskovic L, Maric P, Ozretic P, Oreskovic D, Ajdukovic M, Levanat S. Assessing the clinical significance of tumor markers in common neoplasms. Frontiers in bioscience (Elite edition). 2012 Jun 1:4(7):2558-78
[PubMed PMID: 22652661]
[51]
Boime I, Ben-Menahem D. Glycoprotein hormone structure-function and analog design. Recent progress in hormone research. 1999:54():271-88; discussion 288-9
[PubMed PMID: 10548880]
[52]
Majumdar A, Mangal NS. Hyperprolactinemia. Journal of human reproductive sciences. 2013 Jul:6(3):168-75. doi: 10.4103/0974-1208.121400. Epub
[PubMed PMID: 24347930]
[53]
Kiriakopoulos A, Giannakis P, Menenakos E. Calcitonin: current concepts and differential diagnosis. Therapeutic advances in endocrinology and metabolism. 2022:13():20420188221099344. doi: 10.1177/20420188221099344. Epub 2022 May 21
[PubMed PMID: 35614985]
Level 3 (low-level) evidence
[54]
Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. The New England journal of medicine. 2019 Aug 8:381(6):552-565. doi: 10.1056/NEJMra1806651. Epub
[PubMed PMID: 31390501]
[55]
Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C, Hanna S, Poitras P, Rayson D, Reid R, Rivera J, Roy A, Shah A, Sideris L, Siu L, Wong R. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Current oncology (Toronto, Ont.). 2006 Apr:13(2):67-76
[PubMed PMID: 17576444]
[56]
Asif S, Teply BA. Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers. 2021 Nov 16:13(22):. doi: 10.3390/cancers13225723. Epub 2021 Nov 16
[PubMed PMID: 34830878]
[57]
Chung MS, Lee SH. Current status of active surveillance in prostate cancer. Investigative and clinical urology. 2016 Jan:57(1):14-20. doi: 10.4111/icu.2016.57.1.14. Epub 2016 Jan 11
[PubMed PMID: 26966722]
[58]
Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. Journal of oncology. 2011:2011():475983. doi: 10.1155/2011/475983. Epub 2011 Apr 11
[PubMed PMID: 21577260]
[59]
Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z. THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER - CLINICAL CONSIDERATIONS. Acta clinica Croatica. 2018 Sep:57(3):518-527. doi: 10.20471/acc.2018.57.03.16. Epub
[PubMed PMID: 31168186]
[60]
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical medicine & research. 2009 Jun:7(1-2):4-13. doi: 10.3121/cmr.2009.825. Epub
[PubMed PMID: 19574486]
[61]
Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F, Gallie BL. Retinoblastoma. Nature reviews. Disease primers. 2015 Aug 27:1():15021. doi: 10.1038/nrdp.2015.21. Epub 2015 Aug 27
[PubMed PMID: 27189421]
[62]
Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes & cancer. 2011 Mar:2(3):344-58. doi: 10.1177/1947601911411084. Epub
[PubMed PMID: 21779504]
[63]
Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. Genes. 2017 Apr 5:8(4):. doi: 10.3390/genes8040116. Epub 2017 Apr 5
[PubMed PMID: 28379189]
[64]
Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Targeting the Bcl-2 family for cancer therapy. Expert opinion on therapeutic targets. 2013 Jan:17(1):61-75. doi: 10.1517/14728222.2013.733001. Epub 2012 Nov 22
[PubMed PMID: 23173842]
Level 3 (low-level) evidence
[65]
Badrick T. Quality leadership and quality control. The Clinical biochemist. Reviews. 2003 Aug:24(3):81-93
[PubMed PMID: 18568046]
Level 2 (mid-level) evidence
[66]
Kinns H, Pitkin S, Housley D, Freedman DB. Internal quality control: best practice. Journal of clinical pathology. 2013 Dec:66(12):1027-32. doi: 10.1136/jclinpath-2013-201661. Epub 2013 Sep 26
[PubMed PMID: 24072731]
Level 2 (mid-level) evidence
[67]
Mrazek C, Lippi G, Keppel MH, Felder TK, Oberkofler H, Haschke-Becher E, Cadamuro J. Errors within the total laboratory testing process, from test selection to medical decision-making - A review of causes, consequences, surveillance and solutions. Biochemia medica. 2020 Jun 15:30(2):020502. doi: 10.11613/BM.2020.020502. Epub
[PubMed PMID: 32550813]
[68]
Abdollahi A, Saffar H, Saffar H. Types and Frequency of Errors during Different Phases of Testing At a Clinical Medical Laboratory of a Teaching Hospital in Tehran, Iran. North American journal of medical sciences. 2014 May:6(5):224-8. doi: 10.4103/1947-2714.132941. Epub
[PubMed PMID: 24926448]
[69]
Vesper HW, Miller WG, Myers GL. Reference materials and commutability. The Clinical biochemist. Reviews. 2007 Nov:28(4):139-47
[PubMed PMID: 18392124]
[70]
Miller WG. The role of proficiency testing in achieving standardization and harmonization between laboratories. Clinical biochemistry. 2009 Mar:42(4-5):232-5. doi: 10.1016/j.clinbiochem.2008.09.004. Epub
[PubMed PMID: 19863911]
[71]
Ionescu G, Neguţ M, Combiescu AA. [Biosafety and biosecurity in the medical laboratory. Update and trends]. Bacteriologia, virusologia, parazitologia, epidemiologia (Bucharest, Romania : 1990). 2007 Jul-Dec:52(3-4):91-9
[PubMed PMID: 19326721]